Evidence of massive leukemic progenitor expansion in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)
A. Turhan, P. Hugues, N. Sorel, C. Desterke, J. H. Bourhis, A. Bennaceur Griscelli, J. C. Chomel
Abstract
Chronic myeloid leukemia (CML) represents one of the major success stories of targeted therapies of the 21st century with the use of tyrosine kinase inhibitors (TKIs). Following discontinuation of TKIs in deep molecular remission context, at least half of the patients experience molecular relapse. Cellular events occurring during this phase are not yet established. In this work, we show a massive amplification of clonogenic progenitors or CFCs (colony-forming cells) in the peripheral blood of patients in molecular recurrence after a TKI discontinuation. We demonstrate, by qRT-PCR analysis on individual and pooled CFCs, that leukemic clonogenic progenitor expansion in the peripheral blood represents the first cellular event before any evidence of cytological change. These findings also suggest that the amplification of the leukemic clone during the first stages of CML takes place not only in the bone marrow but also in the peripheral blood.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanism of treatment-free remission in patients with chronic myeloid leukemia revealed by a computational model of CML evolution
- Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
R. Warfvinge, L. Geironson Ulfsson, … G. Karlsson·bioRxiv·Aug 16, 2023
- Inferring immunological control mechanisms from TKI dose alterations in CML patients
Tom Hähnel, Christoph Baldow, … Ingmar Glauche·bioRxiv·Aug 1, 2019
- Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
Jonathan Rodriguez, Abdon Iniguez, … Richard A. Van Etten·eLifePeer-reviewed·Apr 28, 2023
- To cure or not to cure: consequences of immunological interactions in CML treatment
Artur C. Fassoni, Ingo Roeder, Ingmar Glauche·Bulletin of Mathematical BiologyPeer-reviewed·May 1, 2019
- Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy
E. Gomez-Castaneda, S. Rogers, … T. Holyoake·CancersPeer-reviewed·Oct 26, 2022